FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease
Bellinda L. King‐Kallimanis, Tanya Wroblewski, Virginia E. Kwitkowski, R. Angelo de Claro, Thomas Gwise, Vishal Bhatnagar, Ann T. Farrell, Paul G. Kluetz
Topics & Concepts
IbrutinibQuality of Life ResearchMedicinePublic healthDiseaseInternal medicineOncologyChronic lymphocytic leukemiaPathologyLeukemiaChronic Lymphocytic Leukemia ResearchChronic Myeloid Leukemia TreatmentsLymphoma Diagnosis and Treatment